Halberd Files Provisional Patent Application - Furthering Efforts on Alzheimer's Disease

Rhea-AI Summary

Halberd Corp. (OTC PINK:HALB) has filed a U.S. joint provisional patent application for a novel treatment for Alzheimer's Disease using extracorporeal radio frequency. Developed through research at Arizona State University and Youngstown State University, the technology uses radio frequency waves to target and eliminate Alzheimer's-related antigens from bodily fluids.

Dr. Mitchell S. Felder, CTO, highlighted the promising results of their testing, while William A. Hartman, CEO, emphasized the reduced side effects associated with this treatment approach.

Positive

• Filing of a joint provisional patent application for Alzheimer's treatment demonstrates innovation.
• Promising preliminary results from tests at ASU and YSU.
• The technology could reduce or eliminate side effects associated with conventional treatments.

Negative

• None.

JACKSON CENTER, PA / ACCESSWIRE / August 23, 2021 / Halberd Corp. (OTC PINK:HALB) announced filing a U. S. joint provisional patent application, "Treating Alzheimer's Disease Utilizing Extracorporeal Radio Frequency." The innovation is a result of Halberd's Sponsored Research conducted at Arizona State University (ASU) and Youngstown State University (YSU). The provisional patent application covers technology developed to treat blood or cerebral spinal fluid extracorporeally through exposure to, and elimination via, radio frequency (RF) waves or laser emissive energy.

Dr. Mitchell S. Felder, Halberd Corporation's Chief Technical Officer and co-inventor of the technology, stated, "The conjugation of a metallic nanoparticle with an antibody targets specific Alzheimer's Disease-related antigens. The conjugated antibody/particles bind to the target antigens within the bodily fluid. The treated bodily fluid is then exposed to tuned radio frequency waves or laser energy which causes the conjoined metallic nanoparticles to heat up, thereby destroying the target antigens. Elimination of the target antigens slows or arrests the progression of the disease. We are excited by the very promising results of our testing of this technology to date at YSU and ASU."

William A. Hartman, Chairman, President & CEO of Halberd Corporation, added, "Halberd's patented extracorporeal treatment process permits us, exclusively, to target and treat specific diseases outside of the body. This approach reduces or eliminates any potential dangerous side-effects from standard treatments, such as drugs introduced into the body administered orally, or injected. This latest filing is Halberd's tenth provisional patent application submitted in a little over a year. Each such patent evidences the incremental success of Halberd's unique and exclusive strategy. Halberd's testing of the process to eradicate Alzheimer's Disease antigens through RF and/or laser exposure, continues in conjunction with YSU. ASU then verifies YSU's eradication in test samples. We have experienced encouraging results to date in successfully eradicating select Alzheimer's Disease antigens and continue to fine tune the process before moving on to other target antigens."

To get the latest news on Halberd's exciting developments, including our ongoing disease eradication accomplishments, subscribe by submitting this form.
(https://halberdcorporation.com/contact-us/)

For more information please contact:
William A. Hartman
w.hartman@halberdcorporation.com
support@halberdcorporation.com
www.halberdcorporation.com
Twitter:@HalberdC

About Halberd Corporation.

Halberd Corporation (OTC PINK:HALB), is a publicly traded company on the OTC Market, and is in full compliance with OTC Market reporting requirements. It holds the exclusive worldwide rights to several patent- and PCT-pending extracorporeal treatments for COVID-19 and other medical maladies:

Halberd also holds the exclusive rights to the underlying granted U.S. Patent 9,216,386 and U.S. Patent 8,758,287.

Safe Harbor Notice
Certain statements contained herein are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). The Companies caution that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates made by management. Actual results could differ materially from current projections or implied results. The Companies undertake no obligation to revise these statements following the date of this news release.

SOURCE: Halberd Corporation

View source version on accesswire.com:
https://www.accesswire.com/660857/Halberd-Files-Provisional-Patent-Application--Furthering-Efforts-on-Alzheimers-Disease

FAQ

What is the recent patent application filed by Halberd Corp. (HALB)?

Halberd Corp. filed a U.S. provisional patent application for treating Alzheimer's Disease utilizing extracorporeal radio frequency.

What are the key benefits of Halberd's new Alzheimer's treatment?

The treatment aims to specifically target and eliminate Alzheimer's-related antigens, potentially reducing side effects compared to traditional drug therapies.

When was the patent application filed by Halberd Corp.?

The patent application was filed on August 23, 2021.

What universities are involved in Halberd's Alzheimer's research?

Research for the Alzheimer's treatment is conducted at Arizona State University and Youngstown State University.

What technology does Halberd's provisional patent application cover?

The technology covers treating blood or cerebral spinal fluid with radio frequency waves or laser energy to eliminate target antigens.